BULLFROG AI HLDGS INC Stock Price, News & Analysis

BullFrog AI Holdings (NASDAQ: BFRG), a technology-enabled drug development company leveraging AI and machine learning for pharmaceutical development, has announced its participation in BTIG's Annual Virtual Biotechnology Conference.

CEO Vin Singh will engage in a fireside chat on Wednesday, July 30, 2025, at 11:20 a.m. ET. The company will also be available for one-on-one meetings during the two-day conference, scheduled for July 29-30, 2025.

BullFrog AI (NASDAQ: BFRG) has released a white paper outlining a new approach to drug development using their proprietary bfLEAP™ platform. The platform, built on technology from Johns Hopkins University Applied Physics Lab, addresses the critical issue of high failure rates in drug development, where 90% of candidates fail in clinical trials.

The company's AI solution operates in a $200B+ market and is specifically designed for biological applications, offering composition-aware analytics across the entire drug development lifecycle. The platform's capabilities span early discovery, preclinical trials, and late-stage development, powered by causal AI and combinatorial modeling. With the AI drug discovery market projected to reach $35 billion by 2034, BullFrog AI's technology aims to reduce failure rates and accelerate development cycles through transparent, biology-native analytics.

BullFrog AI Holdings (NASDAQ: BFRG) announces an exclusive investor webinar scheduled for July 23, 2025, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature CEO Vin Singh discussing the company's AI-driven drug development platforms.

Key highlights include the recently launched BullFrog Data Networks™ Solutions Library, powered by their proprietary bfLEAP™ causal AI engine, and the new bfPREP™ module for automated data processing. The company will also discuss its strategic partnership with Sygnature Discovery, aimed at expanding international presence in the $204 billion biopharma R&D market.

BullFrog AI (NASDAQ: BFRG) has launched bfPREP™, a new AI-powered data preparation module within its BullFrog Data Networks™ Solutions Library. The module, developed from the company's experience in a late-stage oncology trial, addresses the challenge of preparing fragmented clinical trial data for AI analysis.

bfPREP™ targets a rapidly growing market expected to reach $6.8 billion by 2029, up from $3.1 billion in 2024. The solution features biomedical-first intelligence, end-to-end automation, standards-based interoperability, and cloud-ready deployment options. It's designed to transform raw clinical, omics, and real-world datasets into analysis-ready insights, significantly reducing data preparation time from months to days.

BullFrog AI (NASDAQ: BFRG) has announced the launch of its new BullFrog Data Networks™ Solutions Library, an enterprise-scale evolution of its AI-powered biomedical insights platform. Set to launch in late 2025, the platform features native deployment support across major cloud services including Google Cloud, Microsoft Azure, and AWS.

The platform is organized into specialized solution modules for different aspects of drug discovery and development, leveraging the company's bfLEAP™ causal AI engine. The solution is specifically designed for large pharmaceutical and biotechnology organizations, offering scalable infrastructure for analyzing complex biomedical datasets.

This development positions BullFrog AI in the rapidly growing AI drug discovery market, which is projected to reach $35.4 billion by 2034 with a 29.6% CAGR.

BullFrog AI Holdings (NASDAQ: BFRG) announced that Dr. Juan Felipe Beltrán, Director of AI, Machine Learning, and Innovation, will be the featured speaker at an upcoming XTalks webinar focused on AI in Bioinformatics. The webinar will address critical pitfalls in AI-driven bioinformatics workflows, including compositional data management, machine learning feature interpretation, and generative AI applications. Dr. Beltrán's expertise supports BullFrog AI's bfLEAP platform and BullFrog Data Networks, which aim to improve drug development success rates beyond the current 12% success rate for drugs entering Phase 1 clinical trials. The presentation will focus on enhancing accuracy and reproducibility in bioinformatics analyses, targeting professionals in bioinformatics, biostatistics, and data science.

BullFrog AI Holdings (NASDAQ: BFRG) has announced a strategic collaboration with UK-based CRO Sygnature Discovery to introduce BullFrog Data Networks, an AI-driven data insights platform, to Sygnature's global biopharma clients. The collaboration is expected to generate $15-30 million in revenue for BullFrog AI through 2028. BullFrog Data Networks, powered by the bfLEAP engine, helps accelerate drug discovery by analyzing complex datasets to uncover hidden relationships and pathways in disease biology. The platform supports various research applications including target identification, mechanism-of-action studies, patient stratification, and clinical trial optimization. This partnership aims to serve small to mid-sized biopharma companies, targeting an underserved market segment in bioinformatics solutions.

Bullfrog AI Holdings (NASDAQ: BFRG) has announced an exclusive live investor webinar and Q&A session scheduled for April 23, 2025, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature CEO Vin Singh discussing the company's innovative approach to drug development using AI and machine learning.

The presentation will showcase their proprietary bfLEAP™ platform, developed at Johns Hopkins Applied Physics Lab and a finalist for the R&D 100 Awards. This platform helps biopharma companies analyze high-dimensional, multi-modal data to optimize clinical strategies. The company's growth strategy focuses on two main areas: generating recurring revenue through their Data Networks platform and developing licensed drug assets in partnership with leading research institutions.

BullFrog AI Holdings (NASDAQ: BFRG) has entered into a collaboration agreement with Eleison Pharmaceuticals to optimize their Phase 3 clinical trial. The partnership will utilize BullFrog's Data Networks™ AI solution, powered by the bfLEAP® platform, to analyze clinical data from Eleison's ongoing Phase 3 trial of glufosfamide for pancreatic cancer.

The AI platform will focus on:

• Evaluating trial trajectory regarding safety signals
• Extracting predictive biomarkers for efficacy and safety
• Supporting future trial design
• Providing data-driven insights for Eleison's planned clinical trials

Glufosfamide, a third-generation alkylating agent, is being evaluated for second-line treatment of pancreatic cancer, which affects over 67,000 Americans and 510,000 people worldwide annually, with five-year survival rates below 5%. Eleison expects to complete the Phase 3 trial in 2027.